Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on AUTOLUS THERAPEUTICS PLC stock.
Autolus Therapeutics plc (Nasdaq: AUTL) generates frequent news as an early commercial-stage biopharmaceutical company focused on next-generation programmed T cell therapies for cancer and autoimmune disease. News coverage for AUTL often centers on AUCATZYL® (obecabtagene autoleucel; obe-cel), the company’s CD19-directed CAR T cell therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and on the clinical and commercial progress of this product.
Investors and healthcare observers following Autolus news will see updates on AUCATZYL net product revenue, treatment center activation, and reimbursement developments such as NICE recommendations and conditional marketing authorizations in the UK and EU. Press releases also describe real-world data from consortia like ROCCA, which evaluate safety and response rates for AUCATZYL in clinical practice, alongside analyses from the FELIX study that explore CAR T-cell persistence and product cell phenotypes as potential predictors of long-term outcomes.
Autolus regularly reports clinical data from its broader pipeline, including the CATULUS trial in pediatric relapsed or refractory B-ALL, the CARLYSLE Phase 1 study in severe refractory systemic lupus erythematosus, the LUMINA Phase 2 trial in lupus nephritis and the BOBCAT trial in progressive multiple sclerosis. These updates typically highlight remission rates, safety profiles, B-cell depletion and immune reset signals in autoimmune indications. Additional news items cover collaborations, such as the evaluation of Cellares’ automated Cell Shuttle platform to support high-throughput CAR T manufacturing, and corporate developments including leadership appointments and participation in healthcare conferences.
This news page allows readers to track Autolus’ ongoing clinical milestones, regulatory and reimbursement decisions, manufacturing initiatives and financial disclosures related to its T cell therapy programs. For those monitoring AUTL, the flow of updates provides context on how AUCATZYL and pipeline candidates are progressing across hematologic malignancies, solid tumors and autoimmune diseases.
Autolus Therapeutics (Nasdaq: AUTL) reported its Q2 2021 financial results, revealing a net loss of $33.2 million, or $(0.47) per share, an improvement from $(0.62) per share in the prior year. Cash reserves totaled $216.4 million, projected to fund operations into H1 2023. Promising updates on the obe-cel therapy highlighted a 50% event-free survival rate in adult acute lymphoblastic leukemia patients after 24 months and successful outcomes in B-cell non-Hodgkin lymphoma trials. The company anticipates pivotal data from ongoing trials in 2022.
Autolus Therapeutics has entered an exclusive licensing agreement with Moderna for up to four immuno-oncology targets, permitting Moderna to develop and commercialize mRNA therapeutics utilizing Autolus' proprietary binders.
Autolus will receive upfront payments for each licensed target, along with milestone payments for successful commercialization, plus royalties on net sales. This partnership underscores Autolus' innovative positioning in the biopharmaceutical field, particularly in cancer treatment technologies.
Autolus Therapeutics (AUTL) announced the appointment of Dr. Edgar Braendle as Chief Development Officer, effective immediately. His expertise in oncology development is expected to propel the company's lead program, obe-cel, through its pivotal study aimed at treating relapsed/refractory adult Acute Lymphoblastic Leukemia (ALL). Dr. Braendle previously held leadership roles at Sumitomo Dainippon Pharma Oncology and Boston Biomedical. His experience includes managing global oncology programs and a strong background in clinical affairs. Autolus aims to advance its proprietary CAR T cell therapies.
Autolus Therapeutics plc (Nasdaq: AUTL) will release its second quarter 2021 financial results and operational highlights on August 5, 2021, before U.S. market open. A conference call will follow at 8:30 AM EDT to discuss these results. CEO Christian Itin will also participate in a panel discussion on July 14, 2021, at the William Blair Biotech Focus Conference 2021. Autolus specializes in developing advanced programmed T cell therapies for cancer treatment, leveraging proprietary programming technologies for improved efficacy against malignancies.
Autolus Therapeutics (Nasdaq: AUTL) announced that its CAR T cell therapy, AUTO1 (obe-cel), has received innovative licensing and access pathway (ILAP) designation from the UK MHRA. This designation is part of the regulatory body’s initiative to expedite the development of promising medicines.
CEO Dr. Christian Itin highlighted that this is a crucial step in accelerating the review process for obe-cel, which is currently under investigation for relapsed/refractory adult B-cell Acute Lymphocytic Leukemia (ALL) in a Phase 1b/2 study.
Autolus Therapeutics (AUTL) reported a 100% complete remission rate in patients with indolent B Cell Non-Hodgkin lymphoma, alongside robust CAR T engraftment. No severe Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) occurred. In adult Acute Lymphoblastic Leukemia (ALL), 85% achieved minimal residual disease-negative complete remission. The event-free survival rate at 12 months is 50.2%, indicating potential for obe-cel as a transformative therapy. A conference call on findings will be held on June 11.
Autolus Therapeutics (NASDAQ: AUTL) announced insights from a Nature Cancer publication on the durability of acute lymphoblastic leukemia (ALL) treatments using AUTO1. The findings reveal that long-term response in pediatric ALL patients correlates with an enrichment of Stem Cell Memory T cells (TSCM). These TSCM cells are believed to support sustained immune response. AUTO1's design encourages efficient targeting and minimized T cell exhaustion, enhancing its therapeutic potential. The investigational therapy is being evaluated in ongoing clinical trials.
Autolus Therapeutics (Nasdaq: AUTL) announced its Annual General Meeting (AGM) scheduled for June 18, 2021, at its headquarters in White City, London. Due to COVID-19 restrictions, in-person attendance is prohibited, and a minimum quorum of two shareholders is required. Shareholders are encouraged to submit proxy votes ahead of the meeting as voting during the AGM will not be possible. No webcast will be provided this year, and results will be announced via press release afterwards.
Autolus Therapeutics plc (Nasdaq: AUTL) announced a 100% complete remission rate in a cohort of patients with relapsed/refractory indolent B cell lymphomas (IBCL) treated with its investigational therapy, AUTO1. The early results were presented at the European Hematology Association Virtual Congress on June 9-17, 2021. Of the 10 patients treated, 9 were evaluable, and 8 remain in ongoing remission at a median of 3.1 months. Importantly, no high-grade cytokine release syndrome or neurotoxicity was observed, indicating a favorable safety profile for AUTO1.
Autolus Therapeutics (Nasdaq: AUTL) reported Q1 2021 results, showing a net loss of $33.3 million or $(0.53) per share. Cash reserves amounted to $239 million, up from $153.3 million at year-end 2020. The company is focusing on its AUTO1 program, with upcoming data expected in 2022 from pivotal studies. The firm also received PRIME designation for AUTO1 in the EU, and innovative licensing for AUTO4 in PTCL. Operational changes aim to save $15 million annually. A follow-on public offering generated $106.9 million in February 2021. Management expects cash runway to last into H1 2023.